- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01711671
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Pilot Study of DKN-01 and Lenalidomide (Revlimid®)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Emory University Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02115
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Forente stater, 02114
- Massachusetts General Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Relapsed or refractory Multiple Myeloma (MM)
a. Treated with at least 1 prior regimen for myeloma
- Prior treatment with bortezomib (Velcade) is acceptable with a wash-out of 2 weeks
- Treatment with prior autologous transplant is permitted
- If a transplant is used as consolidation following chemotherapy, without intervening disease progression, it will be considered 1 line of treatment with the preceding chemotherapy
Diagnosis of symptomatic MM as defined by the International Myeloma Working Group (IMWG) :
- Second line or greater/Refractory/Relapsed, Stage I, Stage II, Stage III
- Measureable disease as indicated by monoclonal protein in the serum of greater than or equal to (≥) 1 grams per deciliter (g/dL), involved serum free light chain assay ≥10 mg/dL (≥100 mg/L) provided the serum free light chain ratio is abnormal; monoclonal light chain in the urine protein electrophoresis of ≥ 200 mg/24 hours, or measurable plasmacytoma
- At least 1 osteolytic bone lesion
- Disease-free of active second/secondary or prior malignancies for equal to or over 5 years with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in-situ" of the cervix or breast
- Ambulatory patients greater than or equal to (≥) 30 years of age
- Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale
- Estimated life expectancy of ≥ 26 weeks
Adequate organ function including:
Hematologic:
- Absolute neutrophil count (ANC) greater than or equal to (≥) 1000/microliter
- Platelet (PLT) count ≥ 75,000/microliter
- Hemoglobin (Hgb) ≥ 8.0 g/dL
Acceptable coagulation status:
- Prothrombin time (PT) and partial thromboplastin time (PTT) ≤ 1.2 x the upper limit of normal (ULN) unless receiving anticoagulation therapy. If receiving anticoagulation therapy, eligibility will be based upon International Normalization Ratio (INR)
International normalized ratio (INR) less than or equal to (≤) 1.6 (unless receiving anticoagulation therapy)
- If receiving warfarin: INR ≤ 3.0 (and no active bleeding, [i.e., no bleeding within 14 days prior to first dose of study therapy])
Hepatic:
- Bilirubin ≤ 1.5 x ULN
- Alanine Transaminase (ALT) and Aspartate Transaminase (AST) ≤ 2.5 x ULN (if liver metastases are present, then ≤ 5 x ULN is allowed)
Renal:
- Calculated creatinine clearance ≥ 45 mL using the Cockcroft and Gault Method
Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 10 to 14 days and again within 24 hours of starting study drug
- WCBP must agree to have pregnancy tests monthly (every 14 days for women with irregular cycles) while on study drug and 4 weeks after the last dose of study drug
- Men must also agree to use a condom if their partner is of child bearing potential, even if they have had a successful vasectomy
- Males and females with reproductive potential must agree to use medically approved contraceptive precautions starting 4 weeks prior to initiation of the therapy and during the trial and for 18 months following the last dose of study drug
- Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Provide written informed consent prior to any study-specific procedures
- Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
Exclusion Criteria:
- Received treatment with an investigational drug, which has not received regulatory approval for any indication, within 28 days of study treatment with DKN-01
- Received any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within 56 days of entry
- Previously treated with an anti-Dickkopf-1 (anti-DKK-1) or antibody therapy, or have had a significant allergy to a known pharmaceutical therapy that, in the opinion of the Investigator, poses an increased risk to the patient
- Received radiation therapy, surgery, or chemotherapy within 2 weeks prior to study entry (6 weeks for nitrosoureas or Mitomycin C)
- Received bisphosphonates (e.g., etidronate, clodronate, tiludronate, pamidronate, neridronate, olpadronate, alendronate, ibandronate, risedronate, zoledronate) within 2 weeks prior to study entry
- Symptomatic central nervous system (CNS) malignancy or metastasis. Patients with treated CNS metastases are eligible provided their disease is radiographically stable, asymptomatic, and they are not currently receiving corticosteroids and/or anticonvulsants. Screening of asymptomatic patients without a history of CNS metastases is not required
- Have a history of major organ transplant (for example: heart, lungs, liver, and kidney)
- Are pregnant or nursing
- Known to be human immunodeficiency virus (HIV) positive, have hepatitis B surface antigen (HBSAg), or hepatitis C antibodies (HCAb)
- Active, uncontrolled bacterial, viral, or fungal infections, including urinary tract infection, within 7 days of study entry requiring systemic therapy
- Serious cardiac condition such as myocardial infarction within the past 6 months, unstable angina, or Class III or IV congestive heart failure as defined by the New York Heart Association (NYHA); have ECG abnormalities including baseline 12-lead ECG with Fridericia-corrected QT interval (QTcF) > 470 msec (female) or > 450 msec (male), a history of congenital long QT syndrome, or any ECG abnormality that, in the opinion of the Investigator, would preclude safe participation in the study
- History of osteonecrosis of the hip or have evidence of structural bone abnormalities in the proximal femur on MRI scan that are considered clinically significant or may have an impact on the interpretation of the scan. Degenerative changes of the hip joint are not exclusionary
- Known concomitant disease(s) known to influence calcium metabolism including hyperparathyroidism, hyperthyroidism, Paget's disease of bone, or any other concurrent severe or uncontrolled concomitant medical condition that, in the opinion of the Investigator, would preclude participation in this study
- Patients who are currently receiving lithium chloride (LiCl)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: DKN-01 300mg
DKN-01 plus lenalidomide (Revlimid)/dexamethasone
|
300 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
|
Eksperimentell: DKN-01 600mg
DKN-01 plus lenalidomide (Revlimid)/dexamethasone
|
600 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
|
Aktiv komparator: Standard of Care
Lenalidomide (Revlimid)/dexamethasone
|
Current approved standard of care
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Fluorine F18 sodium fluoride positron emission tomography (NaF-PET/CT) standard uptake value (SUV)
Tidsramme: Pre-study to after 6 months of therapy
|
SUV as measured by NaF-PET/CT in both myeloma bone lesions and normal bone
|
Pre-study to after 6 months of therapy
|
Fluorine F18 sodium fluoride positron emission tomography (NaF-PET/CT) influx constant (Ki)
Tidsramme: Pre-study to after 6 months of therapy
|
Ki as measured by NaF-PET/CT in both myeloma bone lesions and normal bone
|
Pre-study to after 6 months of therapy
|
F18 fluorodeoxyglucose positron emission tomography (FDG-PET/CT) standard uptake value (SUV)
Tidsramme: Pre-study to after 6 months of therapy
|
SUV as measured by FDG-PET/CT in both myeloma bone lesions and normal bone
|
Pre-study to after 6 months of therapy
|
Number of patients with treatment emergent adverse events
Tidsramme: Baseline to study completion (approximately 7 months)
|
Baseline to study completion (approximately 7 months)
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Overall response rate (ORR)
Tidsramme: Baseline to study completion (approximately 7 months)
|
Baseline to study completion (approximately 7 months)
|
Progression free survival (PFS)
Tidsramme: Baseline to study completion (approximately 7 months)
|
Baseline to study completion (approximately 7 months)
|
Duration of response
Tidsramme: Baseline to study completion (approximately 7 months)
|
Baseline to study completion (approximately 7 months)
|
Overall survival
Tidsramme: Baseline to study completion (approximately 7 months)
|
Baseline to study completion (approximately 7 months)
|
Pharmacokinetics: area under the concentration - time curve (AUC) of a single dose of DKN-01
Tidsramme: Dosing interval of 2 weeks following the first dose in Cycle 1
|
Dosing interval of 2 weeks following the first dose in Cycle 1
|
Pharmacokinetics: maximum plasma concentration (Cmax) of a single dose of DKN-01
Tidsramme: Dosing interval of 2 weeks following the first dose in Cycle 1
|
Dosing interval of 2 weeks following the first dose in Cycle 1
|
Pharmacokinetics: trough DKN-01 concentrations on Cycle 2 and Cycle 3
Tidsramme: Cycle 2 Day 1 Pre-dose, Cycle 3 Day 1 Pre-dose
|
Cycle 2 Day 1 Pre-dose, Cycle 3 Day 1 Pre-dose
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Paul Whitlock, Theorem Clinical Research
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Kardiovaskulære sykdommer
- Vaskulære sykdommer
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Hematologiske sykdommer
- Hemoragiske lidelser
- Hemostatiske lidelser
- Paraproteinemier
- Blodproteinforstyrrelser
- Multippelt myelom
- Neoplasmer, plasmacelle
- Fysiologiske effekter av legemidler
- Autonome agenter
- Agenter fra det perifere nervesystemet
- Anti-inflammatoriske midler
- Antineoplastiske midler
- Immunologiske faktorer
- Antiemetika
- Gastrointestinale midler
- Glukokortikoider
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Antineoplastiske midler, hormonelle
- Angiogenese-hemmere
- Angiogenesemodulerende midler
- Vekststoffer
- Veksthemmere
- Deksametason
- Lenalidomid
Andre studie-ID-numre
- DEK-DKK1-P101
- DKN-01
- LY2812176 (Healthcare Pharmaceuticals)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Multippelt myelom
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeMyelom-multippel | Myelom, plasmacelleForente stater
-
National Cancer Institute (NCI)FullførtMyelom-multippel | Myelom, plasmacelleForente stater
-
National Cancer Institute (NCI)FullførtMyelom-multippel | Myelom, plasmacelleForente stater
-
National Cancer Institute (NCI)AvsluttetMyelom, multippel | Myelom-multippelForente stater
-
Tel-Aviv Sourasky Medical CenterFullførtPlasmacellemyelom | Myelom-multippel | Myelom multippel | Myelom, plasmacelleIsrael
-
National Cancer Institute (NCI)Georgetown University; Hackensack Meridian HealthAvsluttetMyelom-multippel | Myelom, plasmacelle | MyelomatoseForente stater
-
University of ChicagoNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeStage I Myelom | Stadium II multippelt myelom | Stadium III multippelt myelomForente stater, Canada
-
Sidney Kimmel Cancer Center at Thomas Jefferson...FullførtStage I Myelom | Stadium II multippelt myelom | Stadium III multippelt myelomForente stater
-
University of Southern CaliforniaNational Cancer Institute (NCI); Celgene CorporationAvsluttetStage I Myelom | Stadium II multippelt myelom | Stadium III multippelt myelomForente stater
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TilbaketrukketStage I Myelom | Stadium II multippelt myelom | Stadium III multippelt myelom
Kliniske studier på DKN-01 300 mg
-
Johannes Gutenberg University MainzLeap Therapeutics, Inc.Ukjent
-
Leap Therapeutics, Inc.TilgjengeligMagekreft | Eggstokkreft | Gastrisk adenokarsinom | Karsinosarkom | Livmorkreft | Adenokarsinom i Gastroøsofageal Junction | Gastroøsofageal kreft | Livmorkreft | Neoplasma i spiserøret | PlateepitelkarsinomForente stater
-
Leap Therapeutics, Inc.Merck Sharp & Dohme LLCFullførtNeoplasmer i spiserøret | Gastrisk adenokarsinom | Adenokarsinom i Gastroøsofageal Junction | Plateepitelkarsinom | Gastroøsofageal kreftForente stater
-
Leap Therapeutics, Inc.FullførtMultippelt myelom | Ikke-småcellet lungekreft | Solide svulsterForente stater
-
Leap Therapeutics, Inc.FullførtEggstokkreft | Karsinosarkom | Livmorkreft | LivmorkreftForente stater
-
Zucara Therapeutics Inc.RekrutteringType 1 diabetes mellitus med hypoglykemiForente stater, Canada
-
Ixchelsis LimitedFullførtFor tidlig utløsningForente stater
-
NYU Langone HealthLeap Therapeutics, Inc.Avsluttet
-
Royal Marsden NHS Foundation TrustRekrutteringMetastatisk magekreft | Metastatisk spiserørskreftStorbritannia
-
Ixchelsis LimitedFullført